R 0016/09 of 19.05.2010

European Case Law Identifier: ECLI:EP:BA:2010:R001609.20100519
Date of decision: 19 May 2010
Case number: R 0016/09
Petition for review of: T 0764/06 2009-02-25
Application number: 96924368.2
IPC class: C07D 207/34
Language of proceedings: English
Distribution: Distributed to board chairmen and members (B)
Download: Decision in English
OJ versions: No OJ links found
Other decisions for this case: -
Abstracts for this decision: -
Application title: Crystalline R-(R*,R*)-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-(phenylamino) carbonyl-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
Applicant name: Warner-Lambert Company LLC
Opponent name: Teva Pharmaceutical Industries Ltd.
LEK Pharmaceutical and Chemical Company d.d.
Board: -
Headnote: -
Relevant legal provisions: European Patent Convention Art 112a(2)(c)European Patent Convention Art 112a(2)(d)European Patent Convention R 104 European Patent Convention R 106Rules of procedure of the Boards of Appeal Art 12Rules of procedure of the Boards of Appeal Art 13
Keywords: Petition for review - clearly unallowable
Catchword: See paragraph 2.2.13
Cited cases: G 0009/92 R 0021/09
Citing cases: R 0018/09 R 0006/11 R 0013/11 R 0019/11 R 0003/12 R 0017/14 R 0005/15 R 0006/15 R 0003/16 R 0003/17 R 0007/18 R 0011/21 R 0006/23 R 0009/23 T 0453/08 T 0160/09 T 0028/10 T 0253/10 T 0518/10 T 1788/10 T 2197/10 T 2436/10 T 0484/11 T 2016/11 T 0409/12 T 1635/13 T 0205/14 T 2256/14 T 1533/15 T 2352/15 T 2600/17 T 0026/22

ORDER

For these reasons it is unanimously decided that:

The petition for review is rejected as clearly unallowable.